News
Public · Published
HEALWELL and WELL Health Announce Competition Bureau has Concluded Its Merger Review and Issued a No Action Letter
HEALWELL AI and WELL Health announced that Canada's Commissioner of Competition concluded the Competition Bureau's review of WELL's acquisition of a majority interest in HEALWELL and issued a No Action Letter on October 22, 2026.
Published:
Updated:
What happened
HEALWELL AI and WELL Health announced that Canada's Commissioner of Competition concluded the Competition Bureau's review of WELL's acquisition of a majority interest in HEALWELL and issued a No Action Letter on October 22, 2026.
Confirmed
Global impact / market context
The No Action Letter removes a regulatory cloud over the combined company, which means investors face less uncertainty about the deal being challenged. That can support management's plans for preventative care and digital health without the distraction and cost of a prolonged competition case.
Analyst inference
The review followed a Federal Court order in December 2025 for records about the transaction, so closure signals the regulator found no current basis to challenge it. For healthcare technology investors, that reduces deal-risk discounting on the shares and makes future capital spending and partnership decisions easier to plan.
Analyst inference
What to watch
- The No Action Letter states the Commissioner does not, at this time, intend to make an application under section 92 of the Competition Act about the transaction, which means the deal can proceed without a current legal challenge. Confirmed
- Watch whether HEALWELL and WELL disclose next steps on integrating Orion Health, since combining operations could change revenue, costs, and cash available for future investments. Proposed
- Track any change in the companies' capital spending or hiring plans now that regulatory approval is clear, because freed-up management attention may accelerate growth projects and affect profit per sale over time. Analyst inference